Accéder au contenu
Merck

P7306

Polyethylene glycol/ dimethyl sulfoxide solution

Hybri-Max™, average mol wt 1,450, 50 % (w/v), 0.2 μm filtered, BioReagent, suitable for hybridoma

Synonyme(s) :

PEG/DMSO Solution, Polyethylene Glycol Solution, Solution of PEG and DMSO

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

A propos de cet article

MDL number:
MFCD00081839
UNSPSC Code:
12161902
PubChem Substance ID:
24898839
NACRES:
NA.75

Principaux documents

Voir toute la documentation
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

Nom du produit

Polyethylene glycol/ dimethyl sulfoxide solution, Hybri-Max™, average mol wt 1,450, 50 % (w/v), 0.2 μm filtered, BioReagent, suitable for hybridoma

InChI key

LYCAIKOWRPUZTN-UHFFFAOYSA-N

InChI

1S/C2H6O2/c3-1-2-4/h3-4H,1-2H2

SMILES string

C(CO)O

grade

Hybri-Max™

sterility

0.2 μm filtered

product line

BioReagent

form

solution

mol wt

average mol wt 1,450

concentration

50 % (w/v)

technique(s)

cell culture | hybridoma: suitable

impurities

endotoxin, tested

storage temp.

2-8°C

Quality Level

200

Catégories apparentées

Application

PEG is used as a fusogen to obtain hybridomas for monoclonal antibody production. Induces cell hybridization.


Recommended for use in a normal fusion protocol requiring 50% PEG and 10% DMSO.

Other Notes

Contains 50% (w/v) polyethylene glycol (Av. Mol. Wt. 1450) and 10% DMSO (v/v) in DPBS without Calcium.

Packaging

Packaged in sealed ampules under nitrogen.

Preparation Note

Solution is ready-to-use. If a less concentrated solution is desired, dilute with sterile DPBS without calcium (D5773). Some precipitate may appear after being exposed to cooler, but should disappear as the solution warms. Solution may be frozen if desired but should first be aliquotted to avoid repeated freeze/thaw cycles.

Legal Information

Hybri-Max is a trademark of Sigma-Aldrich Co. LLC

Classe de stockage

10 - Combustible liquids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number
RNBK7777
069K2320
097K2411
116K2327
062K2300

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Rechercher un(e) COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Wen-Hung Chen et al.
Virology journal, 14(1), 189-189 (2017-10-04)
Dengue virus (DV) infection causes a spectrum of clinical diseases ranging from dengue fever to a life-threatening dengue hemorrhagic fever. Four distinct serotypes (DV1-4), which have similar genome sequences and envelope protein (E protein) antigenic properties, were divided. Among these
Hong Chang et al.
Oncology letters, 22(5), 749-749 (2021-09-21)
The receptor tyrosine kinase, anexelekto (Axl) is involved in tumor cell growth, migration and invasion, and has been associated with chemotherapy resistance, which makes it an attractive target for cancer therapy. In total, six Axl-targeted monoclonal antibodies (mAbs) and two
Indre Kucinskaite-Kodze et al.
Biomolecules, 10(7) (2020-07-12)
The pathogenicity of many bacteria, including Streptococcus pneumoniae, depends on pore-forming toxins (PFTs) that cause host cell lysis by forming large pores in cholesterol-containing cell membranes. Therefore, PFTs-neutralising antibodies may provide useful tools for reducing S. pneumoniae pathogenic effects. This
Shudan Wang et al.
Theranostics, 10(15), 6854-6874 (2020-06-20)
Repeated failures of "Aβ-lowering" therapies call for new targets and therapeutic approaches for Alzheimer's disease (AD). We propose to treat AD by halting neuronal death and repairing synapses using a BDNF-based therapy. To overcome the poor druggability of BDNF, we
Liliana R Loureiro et al.
Scientific reports, 8(1), 12196-12196 (2018-08-17)
Incomplete O-glycosylation is a feature associated with malignancy resulting in the expression of truncated glycans such as the sialyl-Tn (STn) antigen. Despite all the progress in the development of potential anti-cancer antibodies, their application is frequently hindered by low specificities
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique